We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
- Authors
Fabbiani, M; Zaccarelli, M; Latini, A; Sterrantino, G; D'Ettorre, G; Grima, P; Mondi, A; Rossetti, B; Borchi, B; Giuliani, M; Antinori, A; De Luca, A; Di Giambenedetto, S
- Abstract
Objectives Despite not being approved in Europe as first-line therapy, the efavirenz ( EFV)-containing single tablet regimen ( STR) is frequently used in clinical practice in naïve patients but few data are available on this strategy. In our study, we aimed to assess the risk of EFV discontinuation in patients starting antiretroviral therapy with STR vs. non STR. Methods This was a multicentre study retrospectively enrolling naïve patients starting EFV+ TDF+ FTC. Patients were followed from the time of treatment initiation to the discontinuation of the EFV-containing regimen, comparing STR vs. non STR. Two different analyses were performed: (A) non STR patients censored at the last observation (switch to STR not considered as the end of observation); (B) non STR patients censored at the time of switch to STR. Results The study included 235 patients, of whom 74 (31.5%) directly started STR. Among patients starting non STR, 108 (67.1%) switched to STR after a median period of 6 months. Forty-four EFV discontinuations were observed (13 among STR vs. 31 among non STR patients). The overall estimated probability of discontinuation was 30% at 5 years, about half (14.8%) of these occurring during the first year. Analysis A did not show significant differences between STR and non STR regarding the probability of efavirenz discontinuation (19.9% vs. 24.7% at 5 years, P = 0.630). In contrast, Analysis B showed that the probability of EFV discontinuation was similar (8.3%) between STR and non STR patients up to 8 months. Thereafter, a significantly higher rate of discontinuation was observed in non STR patients (47.5% vs. 19.9% at 5 years, P = 0.034). Conclusions Our data suggest that an early switch to STR during the first months of treatment could reduce the risk of EFV discontinuation.
- Subjects
EFAVIRENZ; DRUGS; HIV infections; HIV-positive persons; MEDICAL cooperation; PATIENT compliance; RESEARCH; DETOXIFICATION (Substance abuse treatment); RETROSPECTIVE studies; THERAPEUTICS
- Publication
HIV Medicine, 2016, Vol 17, Issue 5, p385
- ISSN
1464-2662
- Publication type
Article
- DOI
10.1111/hiv.12313